Market Research Logo

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

Summary


Both NASH and NAFLD occur largely as a result of prolonged insulin resistance and obesity with approximately 80% of cases being diagnosed in overweight individuals. NASH is a severe form of NAFLD and is likely to become even more of a healthcare burden than it is at present. NASH can lead to liver cirrhosis and ultimately liver failure, which can be fatal if it is not treated quickly.

There are a total of 195 pipeline products in development for NASH and 65 products in development for NAFLD. Across the therapy area there are 158 companies developing products for NASH and 57 companies developing products for NAFLD. Key companies active in this space include Gilead, Novartis and Pfizer.

This report “Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018” provides an overview of the pipeline for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The report provides comprehensive information on the therapeutics under development and key players active in this space, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for NAFLD and NASH therapeutics?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Gastrointestinal Report Coverage
    • Non-Alcoholic Steatohepatitis (NASH) –Overview
    • Non Alcoholic Fatty Liver Disease (NAFLD) –Overview
  • Therapeutics Development
    • Non-Alcoholic Steatohepatitis (NASH)
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH)
        • Table Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH)
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH)
        • Table Number of Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH)
      • Pipeline by Universities/Institutes
        • Table Figure 3: Number of Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH)
        • Table Number of Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH)
      • Products under Development by Companies
        • Table Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH)
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH)
    • Non Alcoholic Fatty Liver Disease (NAFLD)
      • Pipeline Overview
        • Table Figure 4: Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)
      • Pipeline by Companies
        • Table Figure 5: Number of Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD).
        • Table Number of Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD)
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Non Alcoholic Fatty Liver Disease (NAFLD)
      • Products under Development by Companies
        • Table Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD)
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Non Alcoholic Fatty Liver Disease (NAFLD)
  • Therapeutics Assessment
    • Non-Alcoholic Steatohepatitis (NASH)
      • Assessment by Target
        • Table Figure 6: Number of Products by Top 10 Targets, Non-Alcoholic Steatohepatitis (NASH)
        • Table Figure 7: Number of Products by Stage and Top 10 Targets, Non-Alcoholic Steatohepatitis (NASH)
        • Table Number of Products by Stage and Target, Non-Alcoholic Steatohepatitis (NASH)
      • Assessment by Mechanism of Action
        • Table Figure 8: Number of Products by Top 10 Mechanism of Actions, Non-Alcoholic Steatohepatitis (NASH)
        • Table Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Non-Alcoholic Steatohepatitis (NASH)
        • Table Number of Products by Stage and Mechanism of Action, Non-Alcoholic Steatohepatitis (NASH)
      • Assessment by Route of Administration
        • Table Figure 10: Number of Products by Routes of Administration, Non-Alcoholic Steatohepatitis (NASH)
        • Table Figure 11: Number of Products by Stage and Routes of Administration, Non-Alcoholic Steatohepatitis (NASH)
        • Table Number of Products by Stage and Route of Administration, Non-Alcoholic Steatohepatitis (NASH)
      • Assessment by Molecule Type
        • Table Figure 12: Number of Products by Top 10 Molecule Types, Non-Alcoholic Steatohepatitis (NASH)
        • Table Figure 13: Number of Products by Stage and Top 10 Molecule Types, Non-Alcoholic Steatohepatitis (NASH)
        • Table Number of Products by Stage and Molecule Type, Non-Alcoholic Steatohepatitis (NASH)
    • Non Alcoholic Fatty Liver Disease (NAFLD)
      • Assessment by Target
        • Table Figure 14: Number of Products by Top 10 Targets, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Figure 15: Number of Products by Stage and Top 10 Targets, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Number of Products by Stage and Target, Non Alcoholic Fatty Liver Disease (NAFLD)
      • Assessment by Mechanism of Action
        • Table Figure 16: Number of Products by Top 10 Mechanism of Actions, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Number of Products by Stage and Mechanism of Action, Non Alcoholic Fatty Liver Disease (NAFLD)
      • Assessment by Route of Administration
        • Table Figure 18: Number of Products by Routes of Administration, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Figure 19: Number of Products by Stage and Routes of Administration, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Number of Products by Stage and Route of Administration, Non Alcoholic Fatty Liver Disease (NAFLD)
      • Assessment by Molecule Type
        • Table Figure 20: Number of Products by Top 10 Molecule Types, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Figure 21: Number of Products by Stage and Top 10 Molecule Types, Non Alcoholic Fatty Liver Disease (NAFLD)
        • Table Number of Products by Stage and Molecule Type, Non Alcoholic Fatty Liver Disease (NAFLD)
  • Companies Involved in Therapeutics Development
    • Non-Alcoholic Steatohepatitis (NASH)
      • AdAlta Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by AdAlta Ltd
      • Albireo Pharma Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Albireo Pharma Inc
      • Allergan Plc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Allergan Plc
      • Amunix Operating Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Amunix Operating Inc
      • Aquinox Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Aquinox Pharmaceuticals Inc
      • Arcturus Therapeutics Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Arcturus Therapeutics Ltd
      • Ardelyx Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Ardelyx Inc
      • Arisaph Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Arisaph Pharmaceuticals Inc
      • Assembly Biosciences Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Assembly Biosciences Inc
      • AstraZeneca Plc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by AstraZeneca Plc
      • BASF SE
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by BASF SE
      • Betagenon AB
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Betagenon AB
      • Bird Rock Bio Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Bird Rock Bio Inc
      • BLR Bio LLC
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by BLR Bio LLC
      • Boehringer Ingelheim GmbH
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Boehringer Ingelheim GmbH
      • Bristol-Myers Squibb Co
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Bristol-Myers Squibb Co
      • Cadila Healthcare Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Cadila Healthcare Ltd
      • Can-Fite BioPharma Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Can-Fite BioPharma Ltd
      • Cardax Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Cardax Inc
      • Carmot Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Carmot Therapeutics Inc
      • Catabasis Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Catabasis Pharmaceuticals Inc
      • Cerenis Therapeutics Holding SA
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Cerenis Therapeutics Holding SA
      • ChemoCentryx Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by ChemoCentryx Inc
      • CohBar Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by CohBar Inc
      • Connexios Life Sciences Pvt Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Connexios Life Sciences Pvt Ltd
      • ConSynance Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by ConSynance Therapeutics Inc
      • CymaBay Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by CymaBay Therapeutics Inc
      • Daiichi Sankyo Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Daiichi Sankyo Co Ltd
      • Debiopharm International SA
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Debiopharm International SA
      • Dicerna Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Dicerna Pharmaceuticals Inc
      • Dimerix Bioscience Pty Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Dimerix Bioscience Pty Ltd
      • Dong-A Socio Holdings Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Dong-A Socio Holdings Co Ltd
      • DURECT Corp
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by DURECT Corp
      • Eli Lilly and Co
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Eli Lilly and Co
      • Enanta Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Enanta Pharmaceuticals Inc
      • Enyo Pharma SA
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Enyo Pharma SA
      • Exicure Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Exicure Inc
      • Forma Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Forma Therapeutics Inc
      • Galectin Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Galectin Therapeutics Inc
      • Galecto Biotech AB
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Galecto Biotech AB
      • Galmed Pharmaceuticals Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Galmed Pharmaceuticals Ltd
      • Gemphire Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Gemphire Therapeutics Inc
      • Genfit SA
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Genfit SA
      • GenKyoTex SA
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by GenKyoTex SA
      • Gilead Sciences Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Gilead Sciences Inc
      • GlaxoSmithKline Plc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by GlaxoSmithKline Plc
      • GRI Bio Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by GRI Bio Inc
      • Guangdong Zhongsheng Pharmaceutical Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd
      • Hanmi Pharmaceuticals Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Hanmi Pharmaceuticals Co Ltd
      • HemoShear Therapeutics, LLC
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by HemoShear Therapeutics, LLC
      • iCo Therapeutics Inc.
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by iCo Therapeutics Inc.
      • Immuron Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Immuron Ltd
      • Intercept Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Intercept Pharmaceuticals Inc
      • Inventiva
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Inventiva
      • Ionis Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Ionis Pharmaceuticals Inc
      • Kissei Pharmaceutical Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Kissei Pharmaceutical Co Ltd
      • Kyorin Pharmaceutical Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Kyorin Pharmaceutical Co Ltd
      • Madrigal Pharmaceuticals Inc.
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Madrigal Pharmaceuticals Inc.
      • Matinas BioPharma Holdings Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Matinas BioPharma Holdings Inc
      • MedImmune LLC
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by MedImmune LLC
      • Merck & Co Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Merck & Co Inc
      • Metacrine Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Metacrine Inc
      • Mitsubishi Tanabe Pharma Corp
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Mitsubishi Tanabe Pharma Corp
      • Naia Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Naia Ltd
      • NeuroVive Pharmaceutical AB
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by NeuroVive Pharmaceutical AB
      • NGM Biopharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by NGM Biopharmaceuticals Inc
      • Nippon Chemiphar Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Nippon Chemiphar Co Ltd
      • Novartis AG
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Novartis AG
      • NovaTarg Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by NovaTarg Therapeutics Inc
      • Novo Nordisk AS
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Novo Nordisk AS
      • Nuevolution AB
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Nuevolution AB
      • Ocera Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Ocera Therapeutics Inc
      • Oramed Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Oramed Pharmaceuticals Inc
      • Pfizer Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Pfizer Inc
      • Pharmaxis Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Pharmaxis Ltd
      • Promethera Biosciences SA
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Promethera Biosciences SA
      • ProMetic Life Sciences Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by ProMetic Life Sciences Inc
      • Protalix BioTherapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Protalix BioTherapeutics Inc
      • Redx Pharma Plc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Redx Pharma Plc
      • Regulus Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Regulus Therapeutics Inc
      • reMYND NV
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by reMYND NV
      • Ritter Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Ritter Pharmaceuticals Inc
      • Saje Pharma LLC
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Saje Pharma LLC
      • Sancilio & Company Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Sancilio & Company Inc
      • Sanofi
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Sanofi
      • Second Genome Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Second Genome Inc
      • Seres Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Seres Therapeutics Inc
      • Shenzhen HighTide Biopharmaceutical Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Shenzhen HighTide Biopharmaceutical Ltd
      • Shire Plc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Shire Plc
      • Sprint Bioscience AB
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Sprint Bioscience AB
      • Synlogic Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Synlogic Inc
      • TaiwanJ Pharmaceuticals Co Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by TaiwanJ Pharmaceuticals Co Ltd
      • Tiziana Life Sciences Plc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Tiziana Life Sciences Plc
      • TRACON Pharmaceuticals Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by TRACON Pharmaceuticals Inc
      • Translate Bio Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Translate Bio Inc
      • Vascular Biogenics Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Vascular Biogenics Ltd
      • Verlyx Pharma Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Verlyx Pharma Inc
      • Viking Therapeutics Inc
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Viking Therapeutics Inc
      • Zebra Discovery Ltd
        • Table Non-Alcoholic Steatohepatitis (NASH) –Pipeline by Zebra Discovery Ltd
    • Non Alcoholic Fatty Liver Disease (NAFLD)
      • Akcea Therapeutics Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Akcea Therapeutics Inc
      • Allergan Plc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Allergan Plc
      • Ardelyx Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Ardelyx Inc
      • Arisaph Pharmaceuticals Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Arisaph Pharmaceuticals Inc
      • AstraZeneca Plc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by AstraZeneca Plc
      • Betagenon AB
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Betagenon AB
      • Bird Rock Bio Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Bird Rock Bio Inc
      • Boehringer Ingelheim GmbH
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Boehringer Ingelheim GmbH
      • Cadila Healthcare Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Cadila Healthcare Ltd
      • Can-Fite BioPharma Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Can-Fite BioPharma Ltd
      • Cerenis Therapeutics Holding SA
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Cerenis Therapeutics Holding SA
      • CJ HealthCare Corp
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by CJ HealthCare Corp
      • Corcept Therapeutics Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Corcept Therapeutics Inc
      • CymaBay Therapeutics Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by CymaBay Therapeutics Inc
      • Daewoong Pharmaceutical Co Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Daewoong Pharmaceutical Co Ltd
      • Dr. Falk Pharma GmbH
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Dr. Falk Pharma GmbH
      • DURECT Corp
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by DURECT Corp
      • Eli Lilly and Co
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Eli Lilly and Co
      • Enanta Pharmaceuticals Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Enanta Pharmaceuticals Inc
      • Eternygen GmbH
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Eternygen GmbH
      • Evgen Pharma Plc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Evgen Pharma Plc
      • Galmed Pharmaceuticals Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Galmed Pharmaceuticals Ltd
      • Gemphire Therapeutics Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Gemphire Therapeutics Inc
      • Genfit SA
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Genfit SA
      • Gilead Sciences Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Gilead Sciences Inc
      • HemoShear Therapeutics, LLC
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by HemoShear Therapeutics, LLC
      • Huons Global Co Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Huons Global Co Ltd
      • Immuron Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Immuron Ltd
      • Kowa Co Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Kowa Co Ltd
      • Kyorin Pharmaceutical Co Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Kyorin Pharmaceutical Co Ltd
      • Matinas BioPharma Holdings Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Matinas BioPharma Holdings Inc
      • Metacrine Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Metacrine Inc
      • Miyarisan Pharmaceutical Company Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Miyarisan Pharmaceutical Company Ltd
      • Novartis AG
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Novartis AG
      • NovaTarg Therapeutics Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by NovaTarg Therapeutics Inc
      • Ocera Therapeutics Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Ocera Therapeutics Inc
      • Pfizer Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Pfizer Inc
      • Phenex Pharmaceuticals AG
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Phenex Pharmaceuticals AG
      • Renova Therapeutics Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Renova Therapeutics Inc
      • Ritter Pharmaceuticals Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Ritter Pharmaceuticals Inc
      • Sancilio & Company Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Sancilio & Company Inc
      • Shenzhen HighTide Biopharmaceutical Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Shenzhen HighTide Biopharmaceutical Ltd
      • TaiwanJ Pharmaceuticals Co Ltd
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by TaiwanJ Pharmaceuticals Co Ltd
      • TCM Biotech International Corp
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by TCM Biotech International Corp
      • Theratechnologies Inc
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Pipeline by Theratechnologies Inc
  • Dormant Projects
    • Non-Alcoholic Steatohepatitis (NASH)
      • Table Non-Alcoholic Steatohepatitis (NASH) –Dormant Projects
    • Non Alcoholic Fatty Liver Disease (NAFLD)
      • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Dormant Projects
  • Discontinued Products
    • Non-Alcoholic Steatohepatitis (NASH)
      • Table Non-Alcoholic Steatohepatitis (NASH) –Discontinued Products
    • Non Alcoholic Fatty Liver Disease (NAFLD)
      • Table Non Alcoholic Fatty Liver Disease (NAFLD) –Discontinued Products
  • Product Development Milestones
    • Non-Alcoholic Steatohepatitis (NASH)
      • Featured News & Press Releases
    • Non Alcoholic Fatty Liver Disease (NAFLD)
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report